[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insight Molecular Diagnostics Inc (IMDX)

Insight Molecular Diagnostics Inc (IMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,053
  • Shares Outstanding, K 32,290
  • Annual Sales, $ 4,060 K
  • Annual Income, $ -50,220 K
  • EBIT $ -49 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.79
  • Price/Sales 44.67
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 386.85% (+63.64%)
  • Historical Volatility 141.42%
  • IV Percentile 36%
  • IV Rank 29.86%
  • IV High 1,191.63% on 03/11/26
  • IV Low 44.23% on 03/12/26
  • Expected Move (DTE 2) 0.51 (8.95%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 1.77
  • Today's Open Interest 1,656
  • Open Int (30-Day) 1,566
  • Expected Range 5.19 to 6.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.48
  • Growth Rate Est. (year over year) +208,025.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +9.62%
on 06/05/26
6.86 -16.91%
on 05/18/26
-0.71 (-11.08%)
since 05/15/26
3-Month
2.42 +135.54%
on 03/31/26
6.86 -16.91%
on 05/18/26
+0.79 (+16.09%)
since 03/13/26
52-Week
2.33 +144.64%
on 08/29/25
8.51 -33.02%
on 11/12/25
+3.05 (+115.09%)
since 06/13/25

Most Recent Stories

More News
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA alone GraftAssure™ assay doubles reliability...

IMDX : 5.70 (+1.60%)
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specifically Major transplantation conference in Boston...

IMDX : 5.70 (+1.60%)
Insight Molecular Diagnostics: Q1 Earnings Snapshot

Insight Molecular Diagnostics: Q1 Earnings Snapshot

IMDX : 5.70 (+1.60%)
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization

Progressing toward commercialization with third-party head-to-head data publications and GALACTIC registry study engagement Northeast kidney transplant center (among the top 10 in the U.S.) is first to...

IMDX : 5.70 (+1.60%)
iMDx to Release First Quarter 2026 Results on May 13, 2026

NASHVILLE, Tenn., May 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report first quarter 2026 financial results after the market...

IMDX : 5.70 (+1.60%)
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay

Positive real-world head-to-head data on GraftAssure TM assay to be presented at the 39 th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland...

IMDX : 5.70 (+1.60%)
Insight Molecular Diagnostics: Q4 Earnings Snapshot

Insight Molecular Diagnostics: Q4 Earnings Snapshot

IMDX : 5.70 (+1.60%)
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25 Welcomed second favorable head-to-head data set from an independent study at large hospital comparing...

IMDX : 5.70 (+1.60%)
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market...

IMDX : 5.70 (+1.60%)
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score

New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” score outperformed percentage-only measures of...

IMDX : 5.70 (+1.60%)

Business Summary

Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 6.60
2nd Resistance Point 6.29
1st Resistance Point 6.00
Last Price 5.70
1st Support Level 5.40
2nd Support Level 5.09
3rd Support Level 4.80

See More

52-Week High 8.51
Fibonacci 61.8% 6.15
Last Price 5.70
Fibonacci 50% 5.42
Fibonacci 38.2% 4.69
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.